How should biotech companies manage reputation during clinical trials?

Biotech reputation during clinical trials is a controlled-disclosure problem: the science is uncertain, the regulatory rules on what can be said are strict, and the financial stakes make speculation rampant. Messaging has to be scrupulously regulatory-aware, because forward-looking claims about trial outcomes carry both securities and FDA exposure, and the temptation to signal optimism is exactly where companies get into trouble. The reputational risk is misinformation: investors, patients, and patient-advocacy communities discuss trial readouts intensely, and AI engines synthesize that chatter into answers that can misstate where a trial actually stands. We monitor those prompts across the AI engines with AIQ™, watching for the moment speculation about an outcome gets repeated as fact. The constructive work is accurate, compliant content on the underlying science and the broader pipeline, so that the company’s legitimate story has authoritative material in the record rather than leaving the narrative to be written by rumor and short interest.